Antiretroviral pharmacokinetics in pregnant women

Elise M. Gilbert, Kristin M. Darin, Kimberly K Scarsi, Milena M. McLaughlin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

For women infected with the human immunodeficiency virus (HIV) who become pregnant, the use of combination antiretroviral therapy (ART) significantly reduces transmission of HIV from mother to child. Selection of an appropriate ART regimen for use among pregnant women requires consideration of numerous factors including maternal and fetal safety, antiretroviral pharmacokinetics, and regimen efficacy. Optimization of antiretroviral pharmacokinetics during pregnancy requires special consideration because pregnancy-associated changes in drug absorption, distribution, metabolism, and excretion are known to occur throughout pregnancy and postpartum. Understanding antiretroviral placental transfer may offer additional insight into each drug's potential role in preventing HIV transmission in utero and may also have implications regarding viral resistance in cases where transmission does occur. In this review, we summarize key published data describing antiretroviral pharmacokinetics in pregnant women, providing suggestions for clinical application of these data where appropriate.

Original languageEnglish (US)
Pages (from-to)838-855
Number of pages18
JournalPharmacotherapy
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Pregnant Women
Pharmacokinetics
HIV
Pregnancy
Mothers
Pharmaceutical Preparations
Postpartum Period
Safety
Therapeutics

Keywords

  • antiretrovial therapy
  • human immunodeficiency virus
  • pharmacokinetics
  • pregnancy

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Gilbert, E. M., Darin, K. M., Scarsi, K. K., & McLaughlin, M. M. (2015). Antiretroviral pharmacokinetics in pregnant women. Pharmacotherapy, 35(9), 838-855. https://doi.org/10.1002/phar.1626

Antiretroviral pharmacokinetics in pregnant women. / Gilbert, Elise M.; Darin, Kristin M.; Scarsi, Kimberly K; McLaughlin, Milena M.

In: Pharmacotherapy, Vol. 35, No. 9, 01.09.2015, p. 838-855.

Research output: Contribution to journalArticle

Gilbert, EM, Darin, KM, Scarsi, KK & McLaughlin, MM 2015, 'Antiretroviral pharmacokinetics in pregnant women', Pharmacotherapy, vol. 35, no. 9, pp. 838-855. https://doi.org/10.1002/phar.1626
Gilbert, Elise M. ; Darin, Kristin M. ; Scarsi, Kimberly K ; McLaughlin, Milena M. / Antiretroviral pharmacokinetics in pregnant women. In: Pharmacotherapy. 2015 ; Vol. 35, No. 9. pp. 838-855.
@article{81cc8973088a4b379767b369ab680260,
title = "Antiretroviral pharmacokinetics in pregnant women",
abstract = "For women infected with the human immunodeficiency virus (HIV) who become pregnant, the use of combination antiretroviral therapy (ART) significantly reduces transmission of HIV from mother to child. Selection of an appropriate ART regimen for use among pregnant women requires consideration of numerous factors including maternal and fetal safety, antiretroviral pharmacokinetics, and regimen efficacy. Optimization of antiretroviral pharmacokinetics during pregnancy requires special consideration because pregnancy-associated changes in drug absorption, distribution, metabolism, and excretion are known to occur throughout pregnancy and postpartum. Understanding antiretroviral placental transfer may offer additional insight into each drug's potential role in preventing HIV transmission in utero and may also have implications regarding viral resistance in cases where transmission does occur. In this review, we summarize key published data describing antiretroviral pharmacokinetics in pregnant women, providing suggestions for clinical application of these data where appropriate.",
keywords = "antiretrovial therapy, human immunodeficiency virus, pharmacokinetics, pregnancy",
author = "Gilbert, {Elise M.} and Darin, {Kristin M.} and Scarsi, {Kimberly K} and McLaughlin, {Milena M.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/phar.1626",
language = "English (US)",
volume = "35",
pages = "838--855",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Antiretroviral pharmacokinetics in pregnant women

AU - Gilbert, Elise M.

AU - Darin, Kristin M.

AU - Scarsi, Kimberly K

AU - McLaughlin, Milena M.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - For women infected with the human immunodeficiency virus (HIV) who become pregnant, the use of combination antiretroviral therapy (ART) significantly reduces transmission of HIV from mother to child. Selection of an appropriate ART regimen for use among pregnant women requires consideration of numerous factors including maternal and fetal safety, antiretroviral pharmacokinetics, and regimen efficacy. Optimization of antiretroviral pharmacokinetics during pregnancy requires special consideration because pregnancy-associated changes in drug absorption, distribution, metabolism, and excretion are known to occur throughout pregnancy and postpartum. Understanding antiretroviral placental transfer may offer additional insight into each drug's potential role in preventing HIV transmission in utero and may also have implications regarding viral resistance in cases where transmission does occur. In this review, we summarize key published data describing antiretroviral pharmacokinetics in pregnant women, providing suggestions for clinical application of these data where appropriate.

AB - For women infected with the human immunodeficiency virus (HIV) who become pregnant, the use of combination antiretroviral therapy (ART) significantly reduces transmission of HIV from mother to child. Selection of an appropriate ART regimen for use among pregnant women requires consideration of numerous factors including maternal and fetal safety, antiretroviral pharmacokinetics, and regimen efficacy. Optimization of antiretroviral pharmacokinetics during pregnancy requires special consideration because pregnancy-associated changes in drug absorption, distribution, metabolism, and excretion are known to occur throughout pregnancy and postpartum. Understanding antiretroviral placental transfer may offer additional insight into each drug's potential role in preventing HIV transmission in utero and may also have implications regarding viral resistance in cases where transmission does occur. In this review, we summarize key published data describing antiretroviral pharmacokinetics in pregnant women, providing suggestions for clinical application of these data where appropriate.

KW - antiretrovial therapy

KW - human immunodeficiency virus

KW - pharmacokinetics

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84942553082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942553082&partnerID=8YFLogxK

U2 - 10.1002/phar.1626

DO - 10.1002/phar.1626

M3 - Article

C2 - 26297552

AN - SCOPUS:84942553082

VL - 35

SP - 838

EP - 855

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -